Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Varicella zoster virus vaccine for haematological malignancies

Per Ljungman • 26 Oct 2019
COSTEM 2019
General Vaccines

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, discusses the use of an inactivated Varicella-zoster virus vaccine in patients with hematological malignancies for the prevention of shingles and herpes zoster in the post-transplant setting, specifically in the elderly. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Per Ljungman

0:27
What to expect from TCT 2021?
Per Ljungman • 5 Feb 2021
5:37
Stem cell transplantation & cellular therapy during COVID-19 in Europe
Per Ljungman • 5 Feb 2021
1:30
EBMT Project 2020: migration of data
Per Ljungman • 1 Sep 2020
2:46
Letermovir prevents cytomegalovirus (CMV) in transplant patients
Per Ljungman • 24 Aug 2020

Related Videos

3:12
Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh • 25 Apr 2024
4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals